Clinical interest of point-of-care pharmacogenomic testing: Clopidogrel behind warfarin

Pharmacogenomics

Volumn 13, Issue 11, 2012, Pages 1216-1218

  Shahabi, Payman ^a   Siest, Gérard ^a   Visvikis Siest, Sophie ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

clopidogrel; cytochrome P450; genetics; pharmacogenomics; point of care testing; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; CYP2C9 PROTEIN, HUMAN; DRUG DERIVATIVE; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; PHARMACOLOGICAL BIOMARKER; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; BLEEDING; CYP2C9 GENE; DRUG CHOICE; GENE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; LOSS OF FUNCTION MUTATION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMIC TESTING; PHARMACOGENOMICS; POINT OF CARE TESTING; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VKORC1 GENE; BLOOD CLOTTING; DRUG EFFECT; EDITORIAL; GENETICS; HOSPITAL INFORMATION SYSTEM; PHARMACOGENETICS;

ARYL HYDROCARBON HYDROXYLASES; BIOMARKERS, PHARMACOLOGICAL; BLOOD COAGULATION; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POINT-OF-CARE SYSTEMS; TICLOPIDINE; WARFARIN;

EID: 84865518713     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.85     Document Type: Review

References (20)

1. Destenaves B, Thomas F. New advances in pharmacogenomics. Curr. Opin. Chem. Biol. 4, 440-444 (2000). (Pubitemid 30621047)
2. Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry-a useful clinical tool or wishful thinking for the future? Curr. Pharm. Des. 16, 136-144 (2010).
3. Weinshilboum R. Pharmacogenomics of endocrine therapy in breast cancer. Adv. Exp. Med. Biol. 630, 220-231 (2008).
4. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003). (Pubitemid 36159889)
5. SEARCH Collaborative Group, Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy-a genome wide study. N. Engl. J. Med. 359, 789-799 (2008).
6. Howard R, Leathart JB, French DJ et al. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. Clin. Chim. Acta 412, 2063-2069 (2011).
7. Shapiro S. The hypoprothrombinemia-inducing activity of warfarin sodium (coumadin sodium). J. Kans. Med. Soc. 55, 687-691 (1954).
8. Rizk DV, Warnock DG. Warfarin-related nephropathy: another newly recognized complication of an old drug. Kidney Int. 80, 131-133 (2011).
9. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (MedcoMayo warfarin effectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).
10. Johnson JA. Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation 125, 1964-1966 (2012).
11. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
12. Angiolillo DJ. Applying platelet function testing in clinical practice: what are the unmet needs? JAMA 306, 1260-1261 (2011).
13. Kushner FG, Hand M, Smith SC Jr et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 120, 2271-2306 (2009).
14. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and μ-analysis. JAMA 306, 2704-2714 (2011).
15. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol. 45, 1157-1164 (2005). (Pubitemid 40523131)
16. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated μ-analysis. Thromb. Haemost. 103, 841-848 (2010).
17. Miao J, Liu R, Li Z. Cytochrome P450 2C19 polymorphism and clopidogrel after MI. Lancet 373, 1171-1172 (2009).
18. Bouman HJ, Schömig E, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
19. Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members, Holmes DR Jr, Dehmer GJ, Kaul S et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of cardiology foundation task force on clinical expert consensus documents and the American Heart Association. Circulation 122, 537-557 (2010).
20. Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379, 1705-1711 (2012).